Molecular classification of gastric cancer: Towards a pathwaydriven targeted therapy

Oncotarget

Volumn 6, Issue 28, 2015, Pages 24750-24779

  Riquelme, Ismael ^a   Saavedra, Kathleen ^a   Espinoza, Jaime A ^b   Weber, Helga ^a   García, Patricia ^b   Nervi, Bruno ^b   Garrido, Marcelo ^b   Corvalán, Alejandro H ^b   Roa, Juan Carlos ^b   Bizama, Carolina ^b  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cancer stem cells; Chemotherapy; Gastric cancer; Molecular classification; Signaling pathway

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; VASCULOTROPIN; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CHEMORADIOTHERAPY; CHROMOSOMAL INSTABILITY; EPSTEIN BARR VIRUS INFECTION; GENETIC STABILITY; HIPPO SIGNALING PATHWAY; HUMAN; MANAGED CARE; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CLASSIFICATION; DRUG EFFECTS; METABOLISM; PROCEDURES; STOMACH NEOPLASMS; TRENDS;

ENZYME INHIBITORS; ERBB RECEPTORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84944472832     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4990     Document Type: Article

References (259)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
2. Nadauld LD and Ford JM. Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol. 2013; 31(7):838-839.
3. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park do J, Kim JH, Yang HK, Lee BL and Kim WH. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res. 2007; 13(14):4154-4163.
4. The Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-209.
5. Razzak M. Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. Nat Rev Clin Oncol. 2014; 11(9):499.
6. Stock M and Otto F. Gene deregulation in gastric cancer. Gene. 2005; 360(1):1-19.
7. Rivera F, Gravalos C, Garcia-Carbonero R and Seom. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol. 2012; 14(7):528-535.
8. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005; 241(1):27-39.
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345(10):725-730.
10. Goodman KA. Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key. J Clin Oncol. 2015; pii: JCO.2014.59.1941.
11. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012; 30(3):268-273.
12. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ and Participants MT. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20.
13. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E and Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010; 303(17):1729-1737.
14. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K and Group A-G. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-1820.
15. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(12):1389-1396.
16. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J and Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3):CD004064.
17. Garrido M, Fonseca PJ, Vieitez JM, Frunza M and Lacave AJ. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2014; 14(8):887-900.
18. Kang Y, Kang W, Shin D, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G and McCloud P. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009; 20(4):666-673.
19. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9(3):215-221.
20. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015; 26(1):141-148.
21. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008; 26(9):1435-1442.
22. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR and Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United K. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46.
23. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014; 15(1):78-86.
24. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E and Group VS. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25(22):3205-3209.
25. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K and Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008; 19(8):1450-1457.
26. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, et al. Randomized, openlabel, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013; 31(35):4438-4444.
27. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-697.
28. Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, Kim MA, Han SW, Oh DY, Kim TY, Kim WH and Bang YJ. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res. 2012; 32(4):1547-1553.
29. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008; 52(6):738-746.
30. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M and ACTS-GC Group. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18(21):5992-6000.
31. Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, Jimenez U, Alonso V, Garcia-Carbonero R, Sastre J, Colomer R, Cortes-Funes H and Jimeno A. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011; 13(3):179-184.
32. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965; 64:31-49.
33. Correa P. Human Gastric Carcinogenesis: A Multistep and Multifactorial Process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52(24):6735-6740.
34. Peek RM, Jr. and Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006; 208(2):233-248.
35. Gomceli I, Demiriz B and Tez M. (2012). Gastric carcinogenesis. World J Gastroenterol: Baishideng Publishing Group Co., Limited), pp. 5164-5170.
36. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E and Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer. 2001; 4(3):113-121.
37. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004; 157:327-349.
38. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012; 44(5):570-574.
39. Lee YS, Cho YS, Lee GK, Lee S, Kim YW, Jho S, Kim HM, Hong SH, Hwang JA, Kim SY, Hong D, Choi IJ, Kim BC, et al. Genomic profile analysis of diffuse-type gastric cancers. Genome Biol. 2014; 15(4):R55.
40. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, Ichimura T, Ushiku T, Funahashi S, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014; 46(6):583-587.
41. Meining A, Morgner A, Miehlke S, Bayerdorffer E and Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001; 15:983-998.
42. Tang W, Morgan DR, Meyers MO, Dominguez RL, Martinez E, Kakudo K, Kuan PF, Banet N, Muallem H, Woodward K, Speck O and Gulley ML. Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infect Agent Cancer. 2012; 7(1):21.
43. Khan G and Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infect Agent Cancer. 2014; 9(1):38.
44. Iizasa H, Nanbo A, Nishikawa J, Jinushi M and Yoshiyama H. Epstein-Barr Virus (EBV)-associated Gastric Carcinoma. Viruses. 2012; 4(12):3420-3439.
45. Akiba S, Koriyama C, Herrera-Goepfert R and Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 2008; 99(2):195-201.
46. Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014; 63(2):236-243.
47. Arcaro A and Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics. 2007; 8(5):271-306.
48. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4):929-944.
49. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339.
50. Wu H, Huang M, Cao P, Wang T, Shu Y and Liu P. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther. 2012; 13(5):281-288.
51. Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y, Chen Y, Shi Q, Yu G and Zhang X. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 2007; 69(1):19-27.
52. McDermott D and Atkins M. PD-1 as a potential target in cancer therapy. Cancer Med. 2013; 2(5):662-673.
53. Kim JY, Shin NR, Kim A, Lee HJ, Park WY, Kim JY, Lee CH, Huh GY and Park do Y. Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol. 2013; 47(1):28-35.
54. Choi YY, Bae JM, An JY, Kwon IG, Cho I, Shin HB, Eiji T, Aburahmah M, Kim HI, Cheong JH, Hyung WJ and Noh SH. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol. 2014; 110(2):129-135.
55. Falchetti M, Saieva C, Lupi R, Masala G, Rizzolo P, Zanna I, Ceccarelli K, Sera F, Mariani-Costantini R, Nesi G, Palli D and Ottini L. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol. 2008; 39(6):925-932.
56. Yamamoto H, Sawai H and Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1997; 57(19):4420-4426.
57. Gazvoda B, Juvan R, Zupanic-Pajnic I, Repse S, Ferlan-Marolt K, Balazic J and Komel R. Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA. Eur J Gastroenterol Hepatol. 2007; 19(12):1082-1089.
58. Karaman A, Kabalar ME, Binici DN, Ozturk C and Pirim I. Genetic alterations in gastric precancerous lesions. Genet Couns. 2010; 21(4):439-450.
59. French AJ, Petroni G, Thibideau SN, Smolkin M, Bissonette E, Roviello F, Harper JC, Koch BR, Anderson SA, Hebbring SJ and Powell SM. Allelic imbalance of 8p indicates poor survival in gastric cancer. J Mol Diagn. 2004; 6(3):243-252.
60. McLean MH and El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014; 11(11):664-674.
61. Wang K, Yuen ST, Xu JC, Lee SP, Yan HHN, Shi ST, Siu HC, Deng SB, Chu KM, Law S, Chan KH, Chan ASY, Tsui WY, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014; 46(6):573-582.
62. Humar B and Guilford P. Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci. 2009; 100(7):1151-1157.
63. Lin M-T, Lin B-R, Chang C-C, Chu C-Y, Su H-J, Chen S-T, Jeng Y-M and Kuo M-L. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer. 2007; 120(12):2600-2608.
64. Murray D, Horgan G, MacMathuna P and Doran P. NET1-mediated RhoA activation facilitates lysophosphatidic acidinduced cell migration and invasion in gastric cancer. Br J Cancer. 2008; 99(8):1322-1329.
65. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y and Fan D. Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity. Clin Cancer Res. 2004; 10(18):6239-6247.
66. Ayed-Guerfali DB, Hassairi B, Khabir A, Sellami-Boudawara T, Gargouri A and Mokdad-Gargouri R. Expression of APC, beta-catenin and E-cadherin in Tunisian patients with gastric adenocarcinoma: clinical significance. Tumour Biol. 2014; 35(3):1775-1783.
67. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012; 61(5):673-684.
68. Lee SJ, Do IG, Lee J, Kim KM, Jang J, Sohn I and Kang WK. Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013; 8(4):271-280.
69. Yang W, Raufi A and Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 2014; 1846(1):232-237.
70. Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79:34-74.
71. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD and Abbruzzese JL. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006; 24(30):4922-4927.
72. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C and Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol. 2006; 24(10):1612-1619.
73. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R and Jankowski J. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res. 2007; 13(19):5869-5875.
74. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E and Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011; 22(6):1367-1373.
75. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E and Martoni AA. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007; 18(3):510-517.
76. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ and Kim TY. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009; 100(2):298-304.
77. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY and Kang YK. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs. 2011; 29(2):366-373.
78. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F and Peschel C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer. 2010; 102(3):500-505.
79. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):490-499.
80. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A and Baselga J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol. 2004; 22(1):175-184.
81. Trarbach T, Przyborek M, Schleucher N, Heeger S, Lupfert C and Vanhoefer U. Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Invest New Drugs. 2013; 31(3):642-652.
82. Sehrish R. (2014). Gastric Cancer: The Ghosts of Past, Present and Future. Decision Resources Group. Available from: http://decisionresources.com/The-Decision-Resources-Blog/October-2014/Gastric-Cancer-100714.
83. Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, Bokemeyer C, Simon R, Sauter G and Marx AH. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 2015; 15:7.
84. Blagosklonny MV. How Cancer Could be Cured by 2015. Cell Cycle. 2004; 4(2):268-277.
85. Yamada Y. Molecular therapy for gastric cancer. Chin Clin Oncol. 2013; 2(1):5.
86. Takahashi N, Yamada Y, Taniguchi H, Fukahori M, Sasaki Y, Shoji H, Honma Y, Iwasa S, Takashima A, Kato K, Hamaguchi T and Shimada Y. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes. 2014; 7:271.
87. Smyth EC and Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol. 2012; 13(3):377-389.
88. Vu T and Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012; 2:62.
89. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1):39-51.
90. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T and Furukawa H. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014; 110(5):1163-1168.
91. ClinicalTrials.gov, U.S National Institutes of Health. Available from: https://clinicaltrials.gov. Accessed December 2014.
92. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32(19):2039-2049.
93. Hecht JR, Bang YJ, Qin S, Chung HC, Xu J, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, Salman P, Li J, Protsenko S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/ LOGiC J Clin Oncol 31, 2013 (suppl; abstr LBA4001).
94. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3(6):401-410.
95. Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, Hao T, Zhang X, Li M, Zhang F, Li Q, Lu B and Qiao L. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010; 31(6):549-558.
96. Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha TZ, Feng YZ and Zhang K. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol. 2013; 19(13):2073-2079.
97. Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY and Yu W. No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat. 2009; 41(4):218-223.
98. Deguchi K, Ichikawa D, Soga K, Watanabe K, Kosuga T, Takeshita H, Konishi H, Morimura R, Tsujiura M, Komatsu S, Shiozaki A, Okamoto K, Fujiwara H and Otsuji E. Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res. 2010; 30(6):2361-2366.
99. Gou HF, Chen XC, Zhu J, Jiang M, Yang Y, Cao D and Hou M. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Canc Res. 2011; 30:14.
100. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M and Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29(30):3968-3976.
101. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ and Shah MA. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012; 30(17):2119-2127.
102. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet. 2014; 383(9911):31-39.
103. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224-1235.
104. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebocontrolled, parallel-arm, phase II trial. J Clin Oncol. 2013; 31(26):3219-3225.
105. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH and Benson AB, 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010; 28(18):2947-2951.
106. Engelman JA, Luo J and Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619.
107. Liu JF ZX, Chen JH, Yi G, Chen HG, Ba MC, Lin SQ, Qi YC. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol 2010; 16(39):4986-4991.
108. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and Roa J. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Archiv. 2014; 465(1):25-33.
109. Ye B, Jiang L, Xu H, Zhou D and Li Z. Expression of PI3K/ AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol. 2012; 25(3):627-636.
110. Cinti C, Vindigni C, Zamparelli A, Sala D, Epistolato M, Marrelli D, Cevenini G and Tosi P. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Archiv. 2008; 453(5):449-455.
111. Sangawa A, Shintani M, Yamao N and Kamoshida S. Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas. Int J Clin Exp Pathol. 2014; 7(6):3312-3317.
112. Welker ME and Kulik G. Recent syntheses of PI3K/Akt/ mTOR signaling pathway inhibitors. Bioorg Med Chem. 2013; 21(14):4063-4091.
113. Brana I and Siu L. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med. 2012; 10(1):161.
114. Bhattacharya B, Akram M, Balasubramanian I, Tam KKY, Koh KX, Yee MQ and Soong R. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biol Ther. 2012; 13(1):34-42.
115. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P and Broggini M. Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. Cancer Res. 2011; 71(13):4573-4584.
116. She Q, Chandarlapaty S, Ye Q, Lobo J, Haskell K, Leander K, DeFeo-Jones D, Huber H and Rosen N. Breast tumor vells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One. 2008; 3(8):e3065.
117. Li J, Davies B, Han S, Zhou M, Bai Y, Zhang J, Xu Y, Tang L, Wang H, Liu Y, Yin X, Ji Q and Yu D-H. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med. 2013; 11(1):241.
118. Davies B, Greenwood H and Dudley P. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Canc Ther. 2012; 11:873 -887.
119. Liu Y, Sun S, Li J and Yu D. Targeting the PI3K/ AKT Pathway for the Treatment of Gastric Cancer. Chemotherapy. 2014; 3(1):1-6.
120. Lin J, Sampath D and Nannini M. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Canc Res. 2013; 19:1760 -1772.
121. Ma WW and Adjei AA. Novel Agents on the Horizon for Cancer Therapy. CA Cancer J Clin. 2009; 59(2):111-137.
122. Dong M, Phan AT and Yao JC. New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy. Clin Cancer Res. 2012; 18(7):1830-1836.
123. Lang S, Gaumann A and Koehl G. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007; 120:1803 -1810.
124. Sun D, Zhang Y, Tian X, Chen Y and Fang J. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation. Cell Biol Int. 2014; 38(1):50-63.
125. Yoon D, Ryu M and Park Y. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012; 106:1039 -1044.
126. Ohtsu A, Ajani JA, Bai Y-X, Bang Y-J, Chung H-C, Pan H-M, Sahmoud T, Shen L, Yeh K-H, Chin K, Muro K, Kim YH, Ferry D, et al. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. J Clin Oncol. 2013; 31(31):3935-3943.
127. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J and Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118:3065-3074.
128. Wong H and Yau T. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol. 2013; 6(1):15-31.
129. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S and Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011; 10(3):558-565.
130. Park JH, Ryu MH, Park YS, Park SR, Na YS, Rhoo BY and Kang YK. Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression. BMC Cancer. 2015; 15:119.
131. Li V, Wong C and Chan T. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005; 5:29.
132. Oki E. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005; 117:376 -380.
133. Shin J, Kim J, Lee S, Chae H and Kang J. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer. 2010; 10(1):425.
134. Oki E, Kakeji Y and Tokunaga E. Impact of PTEN/AKT/ PI3K signal pathway on the chemotherapy for gastric cancer. J Clin Oncol. 2006; 24(18):4034.
135. Yu H-G, Ai Y-W, Yu L-L, Zhou X-D, Liu J, Li J-H, Xu X-M, Liu S, Chen J, Liu F, Qi Y-L, Deng Q, Cao J, Liu S-Q, Luo H-S and Yu J-P. Phosphoinositide 3-kinase/ Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008; 122(2):433-443.
136. Im S, Lee K and Nam E. Tumori. 2005; 91:513 -521.
137. Sierra JR and Tsao M-S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011; 3(1 Suppl):S21-S35.
138. Sharma N and Adjei AA. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol. 2011; 3(1 Suppl):S37-S50.
139. Comoglio PM, Giordano S and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; 7(6):504-516.
140. Ishibe S, Karihaloo A, Ma H, Zhang J, Marlier A, Mitobe M, Togawa A, Schmitt R, Czyczk J, Kashgarian M, Geller DS, Thorgeirsson SS and Cantley LG. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 2009; 136(2):337-345.
141. Lai AZ, Abella JV and Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009; 19(10):542-551.
142. Wu C, Li A, Chi C, Chung W, Liu T, Lui W and P'eng F. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep. 1998 5(4):817-822.
143. Amemiya H, Kono K, Itakura J, Feng Tang R, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H and Matsumoto Y. c-Met Expression in Gastric Cancer with Liver Metastasis. Oncology. 2002; 63(3):286-296.
144. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T, Miwa K, Endo Y, Yamamoto H and Watanabe H. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer. 1998; 82(11):2112-2122.
145. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T and Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 1999; 85(9):1894-1902.
146. Li Y, Chen C, He Y, Cai S, Yang D, He W, Xu J and Zan W. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012; 106(3):304-310.
147. Kubicka S, Claas C, Staab S, Kühnel F, Zender L, Trautwein C, Wagner S, Rudolph KL and Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002; 47(1):114-121.
148. Huang TJ, Wang JY, Lin SR, Lian ST and Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. Acta Oncol. 2001; 40(5):638-643.
149. Catenacci DVT, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011; 12(1):9-46.
150. Zhao J, Zhang X and Xin Y. Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol. 2011; 26(9):1111-1120.
151. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Holscher AH and Monig SP. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 2008; 19(6):1477-1483.
152. Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K and Yamada Y. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget. 2013; 4(1):9-17.
153. Hack SP, Bruey JM and Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 2014; 5(10):2866-2880.
154. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS and Loh E. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an openlabel, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014; 15(9):1007-1018.
155. Merchant M, Ma X and Maun H. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA. 2013; 110(32):E2987-2996.
156. Martens T, Schmidt N-O, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M and Lamszus K. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo. Clin Cancer Res. 2006; 12(20):6144-6152.
157. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci D, Peterson A, Ratain M, Polite B, Mehnert J and Moss R. Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2014; 20(6):1666-1675.
158. Strickler JH, LoRusso P, Yen CJ, Lin CC, Kang YK, Kaminker P, Ansell P, Bhathena A, Wong S, Dudley MW, Naumovski L and Ramanathan RK. Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 2507).
159. Kang YK, LoRusso P, Salgia R, Yen CJ, Ramanathan RK, Kaminker P, Sokolova I, Bhathena A, Wang L, Naumovski L and Strickler JH. Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC). J Clin Oncol 33, 2015 (suppl 3; abstr 167).
160. Adjei AA, Schwartz B and Garmey E. Early Clinical Development of ARQ 197, a Selective, Non-ATPCompetitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers. The Oncologist. 2011; 16(6):788-799.
161. Kang Y, Muro K, Ryu M, Yasui H, Nishina T, Ryoo B, Kamiya Y, Akinaga S and Boku N. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second-or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs. 2014; 32(2):355-361.
162. Kwak EL, LoRusso P, Hamid O, Janku F, Kittaneh M, Thomas D, Chan E, Bekaii-Saab TS, Amore B, Hwang YC, Tang R, Ngarmchamnanrith G and Hong DS. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. J Clin Oncol 33, 2015 (suppl 3; abstr 1).
163. Hong DS, LoRusso P, Hamid O, Beaupre DM, Janku F, Khan R, Kittaneh M, Lobert RD, Amore B, Caudillo I, Hwang YC, Tang R, Ngarmchamnanrith G and Kwak EL. First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).
164. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M and Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012; 30(4):1352-1360.
165. Qian F, Engst S, Yamaguchi K, Yu P, Won K-A, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, et al. Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases. Cancer Res. 2009; 69(20):8009-8016.
166. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F-C, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A-M, Liu Y, et al. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS One. 2013; 8(3):e54014.
167. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Mol Cancer Ther. 2011; 10(12):2298-2308.
168. Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T and Yano S. Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clin Cancer Res. 2012; 18(6):1663-1671.
169. Molife LR, Dean EJ, Blanco-Codesido M, Krebs MG, Brunetto AT, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, Wood K, de las Heras B and Ranson MR. A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014; 20(24):6284-6294.
170. Sahai E and Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002; 2(2):133-142.
171. Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M and Zheng Y. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci USA. 2013; 110(8):3155-3160.
172. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014; 74(18):2211-2215.
173. Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, Seibel W, Wortman M and Zheng Y. Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol. 2012; 19(6):699-710.
174. Quintas-Cardama A and Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013; 19(8):1933-1940.
175. Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, Gardon O, Tunny KA, Blucher KM, Morton CJ, Parker MW, Sierecki E, Gambin Y, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014; 344(6185):1249783.
176. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-397.
177. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program. 2009:636-642.
178. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008; 22(1):23-30.
179. Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G and Eckhardt SG. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist. 2013; 18(7):819-820.
180. Qian C, Wang J, Yao J, Wang L, Xue M, Liu W and Si J. Involvement of nuclear JAK2 signaling in AG490-induced apoptosis of gastric cancer cells. Anat Rec 2013; 296(12):1865-1873.
181. Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W and Giraud AS. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 2014; 9(5):e95993.
182. Chen T, Yang K, Yu J, Meng W, Yuan D, Bi F, Liu F, Liu J, Dai B, Chen X, Wang F, Zeng F, Xu H, Hu J and Mo X. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res. 2012; 22(1):248-258.
183. Chen W, Zhang X, Chu C, Cheung WL, Ng L, Lam S, Chow A, Lau T, Chen M, Li Y, Nie Y, Wong BC and Pang R. Identification of CD44+ cancer stem cells in human gastric cancer. Hepatogastroenterology. 2013; 60(124):949-954.
184. Liu J, Ma L, Xu J, Liu C, Zhang J, Chen R and Zhou Y. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int J Oncol. 2013; 42(2):453-459.
185. Sun M, Zhou W, Zhang YY, Wang DL and Wu XL. CD44 gastric cancer cells with stemness properties are chemoradioresistant and highly invasive. Oncol Lett. 2013; 5(6):1793-1798.
186. Xu G, Shen J, Ou Yang X, Sasahara M and Su X. Cancer stem cells: the 'heartbeat' of gastric cancer. J Gastroenterol. 2013; 48(7):781-797.
187. Li M, Zhang B, Zhang Z, Liu X, Qi X, Zhao J, Jiang Y, Zhai H, Ji Y and Luo D. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. Biomed Res Int. 2014; 2014:981261.
188. Li K, Dan Z and Nie YQ. Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J Gastroenterol. 2014; 20(18):5420-5426.
189. Huang J and Kalderon D. Coupling of Hedgehog and Hippo pathways promotes stem cell maintenance by stimulating proliferation. J Cell Biol. 2014; 205(3):325-338.
190. Stojnev S, Krstic M, Ristic-Petrovic A, Stefanovic V and Hattori T. Gastric cancer stem cells: therapeutic targets. Gastric Cancer. 2014; 17(1):13-25.
191. Kang DH, Han ME, Song MH, Lee YS, Kim EH, Kim HJ, Kim GH, Kim DH, Yoon S, Baek SY, Kim BS, Kim JB and Oh SO. The role of hedgehog signaling during gastric regeneration. J Gastroenterol. 2009; 44(5):372-379.
192. Song Z, Yue W, Wei B, Wang N, Li T, Guan L, Shi S, Zeng Q, Pei X and Chen L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One. 2011; 6(3):e17687.
193. Tanaka T, Arai M, Minemura S, Oyamada A, Saito K, Jiang X, Tsuboi M, Sazuka S, Maruoka D, Matsumura T, Nakagawa T, Sugaya S, Kanda T, et al. Expression level of sonic hedgehog correlated with the speed of gastric mucosa regeneration in artificial gastric ulcers. J Gastroenterol Hepatol. 2014; 29(4):736-741.
194. Gupta S, Takebe N and Lorusso P. Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2010; 2(4):237-250.
195. Lee SY, Han HS, Lee KY, Hwang TS, Kim JH, Sung IK, Park HS, Jin CJ and Choi KW. Sonic hedgehog expression in gastric cancer and gastric adenoma. Oncol Rep. 2007; 17(5):1051-1055.
196. Sherman AE and Zavros Y. Role of Sonic Hedgehog signaling during progression from inflammation to cancer in the stomach. World J Gastrointest Pathophysiol. 2011; 2(6):103-108.
197. Kim JH, Choi YJ, Lee SH, Shin HS, Lee IO, Kim YJ, Kim H, Yang WI, Kim H and Lee YC. Effect of Helicobacter pylori infection on the sonic hedgehog signaling pathway in gastric cancer cells. Oncol Rep. 2010; 23(6):1523-1528.
198. Kim JH, Shin HS, Lee SH, Lee I, Lee YS, Park JC, Kim YJ, Chung JB and Lee YC. Contrasting activity of Hedgehog and Wnt pathways according to gastric cancer cell differentiation: relevance of crosstalk mechanisms. Cancer Sci. 2010; 101(2):328-335.
199. Yanai K, Nakamura M, Akiyoshi T, Nagai S, Wada J, Koga K, Noshiro H, Nagai E, Tsuneyoshi M, Tanaka M and Katano M. Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett. 2008; 263(1):145-156.
200. Seto M, Ohta M, Asaoka Y, Ikenoue T, Tada M, Miyabayashi K, Mohri D, Tanaka Y, Ijichi H, Tateishi K, Kanai F, Kawabe T and Omata M. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog. 2009; 48(8):703-712.
201. Kim JY, Ko GH, Lee YJ, Ha WS, Choi SK, Jung EJ, Jeong CY, Ju YT, Jeong SH and Hong SC. Prognostic value of sonic hedgehog protein expression in gastric cancer. Jpn J Clin Oncol. 2012; 42(11):1054-1059.
202. Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, Kim JS and Oh SC. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011; 71(22):7061-7070.
203. Saze Z, Terashima M, Kogure M, Ohsuka F, Suzuki H and Gotoh M. Activation of the sonic hedgehog pathway and its prognostic impact in patients with gastric cancer. Dig Surg. 2012; 29(2):115-123.
204. Niu Y, Li F, Tang B, Shi Y, Hao Y and Yu P. Clinicopathological correlation and prognostic significance of sonic hedgehog protein overexpression in human gastric cancer. Int J Clin Exp Pathol. 2014; 7(8):5144-5153.
205. Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, Lv N and Luo S. Suppression of growth and migration by blocking the Hedgehog signaling pathway in gastric cancer cells. Cell Oncol (Dordr). 2013; 36(5):421-435.
206. Bai R, Zhao H, Zhang X and Du S. Characterization of sonic hedgehog inhibition in gastric carcinoma cells. Oncol Lett. 2014; 7(5):1381-1384.
207. Wan J, Zhou J, Zhao H, Wang M, Wei Z, Gao H, Wang Y and Cui H. Sonic hedgehog pathway contributes to gastric cancer cell growth and proliferation. Biores Open Access. 2014; 3(2):53-59.
208. Yoon C, Park do J, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ and Yoon SS. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014; 20(15):3974-3988.
209. Sobanko JF, Okman J and Miller C. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas. J Drugs Dermatol. 2013; 12(10 Suppl):s154-155.
210. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ and Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013; 19(22):6305-6312.
211. Cohen DJ, Christos PJ, Sparano JA, Kindler HL, Catenacci D, Bekaii-Saab TB, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, et al. A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. J Clin Oncol 31, 2013 (suppl 4; abstr 67).
212. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL and Low JA. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013; 19(1):258-267.
213. Brechbiel J, Miller-Moslin K and Adjei AA. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev. 2014; 40(6):750-759.
214. Schepers A and Clevers H. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harb Perspect Biol. 2012; 4(4):a007989.
215. Takahashi-Yanaga F and Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010; 16(12):3153-3162.
216. Anastas JN and Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13(1):11-26.
217. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009; 5(10):e1000676.
218. Mao J, Fan S, Ma W, Fan P, Wang B, Zhang J, Wang H, Tang B, Zhang Q, Yu X, Wang L, Song B and Li L. Roles of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis. 2014; 5:e1039.
219. Bizama C, Benavente F, Salvatierra E, Gutierrez-Moraga A, Espinoza JA, Fernandez EA, Roa I, Mazzolini G, Sagredo EA, Gidekel M and Podhajcer OL. The lowabundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer. Int J Cancer. 2014; 134(4):755-764.
220. Curtin JC and Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 2010; 1(7):552-566.
221. Lenz HJ and Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci. 2014; 105(9):1087-1092.
222. Holland JD, Klaus A, Garratt AN and Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013; 25(2):254-264.
223. Singh SR. Gastric cancer stem cells: a novel therapeutic target. Cancer Lett. 2013; 338(1):110-119.
224. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009; 27(5):1006-1020.
225. Zhang C, Li C, He F, Cai Y and Yang H. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011; 137(11):1679-1686.
226. Yang L, Ping YF, Yu X, Qian F, Guo ZJ, Qian C, Cui YH and Bian XW. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett. 2011; 310(1):46-52.
227. Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, Yoon S, Baek SY, Kim BS, Kang CD and Oh SO. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci. 2011; 68(21):3589-3605.
228. de Sousa EM, Vermeulen L, Richel D and Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011; 17(4):647-653.
229. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G and Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010; 12(5):468-476.
230. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH and Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One. 2013; 8(7):e67811.
231. Kwon MJ and Shin YK. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci. 2013; 14(4):6624-6648.
232. Cui J, Jiang W, Wang S, Wang L and Xie K. Role of Wnt/ beta-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 2012; 18(17):2464-2471.
233. Teng Y, Wang X, Wang Y and Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun. 2010; 392(3):373-379.
234. Koch U and Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci. 2007; 64(21):2746-2762.
235. Kopan R IM. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009; 137(2):216-233.
236. Leong KG and Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2005; 107(6):2223-2233.
237. Kang H, An H, Song J, Kim T, Heo J, Ahn D and Kim G. Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology. 2012; 61(4):576-586.
238. Brzozowa M, Mielanczyk L, Michalski M, Malinowski L, Kowalczyk-Ziomek G, Helewski K, Harabin-Slowinska M, Wojnicz R. Role of Notch signaling pathway in gastric cancer pathogenesis. Contemp Oncol (Pozn). 2013; 17(1):1-5.
239. Du X, Cheng Z, Wang YH, Guo ZH, Zhang SQ, Hu JK and Zhou ZG. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature. World J Gastroenterol. 2014; 20(27):9191-9199.
240. Yeh T, Wu C, Hsu K, Liao W, Yang M, Li AF, Wang A, Kuo M and Chi C. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res. 2009; 69(12):5039-5048.
241. Lee SH, Jeong EG, Yoo NJ and Lee SH. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias. APMIS. 2007; 115(12):1357-1363.
242. Miele L. Notch signaling. Clin Cancer Res. 2006; 12(4):1074-1079.
243. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B and Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008; 27(38):5124-5131.
244. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D and Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806(2):258-267.
245. Shih L and Wang T. Notch Signaling, ?-Secretase Inhibitors, and Cancer Therapy. Cancer Res. 2007; 67(5):1879-1882.
246. Johnson R and Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014; 13(1):63-79.
247. Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer. 2006; 37(4):103-109.
248. Zhang J, Yang YC, Zhu JS, Zhou Z and Chen WX. Clinicopathologic characteristics of YES-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer. Int J Immunopathol Pharmacol. 2012; 25(4):977-987.
249. Song M, Cheong JH, Kim H, Noh SH and Kim H. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res. 2012; 32(9):3827-3834.
250. Xu ZP, Zhu JS, Zhang Q and Wang XY. A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology. 2011; 58(110-111):1611-1617.
251. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-1305.
252. Park HW and Guan KL. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci. 2013; 34(10):581-589.
253. Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW and Pereira SP. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014; 110(7):1698-1704.
254. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):481-489.
255. Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rego S, Brandao C, Carneiro F, Lopes C, Schmitt F and Teixeira MR. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009; 100(3):487-493.
256. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M and Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006; 15(1):65-71.
257. Halon A, Donizy P, Biecek P, Rudno-Rudzinska J, Kielan W and Matkowski R. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. ScientificWorldJournal. 2012; 2012:941259.
258. Xiao L, Wang Y, Li W and Du Y. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Canc Res. 2009; 28(1):152.
259. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H and Xie J. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis. 2005; 26(10):1698-1705.